- RU-58841 was developed by Roussel-Uclaf in the 1980s and has never completed a human clinical trial.
- In March 2026 Kintor reported that pyrilutamide (KX-826) met its Phase 3 primary endpoint in a 666-patient, 24-week trial in China.
- The reported placebo-adjusted gain in that trial was about 10.65 hairs/cm² at the 1.0% concentration, as company top-line data.
- Kintor's 123-man US Phase 2, reported in May 2023, never reported a statistically significant placebo-adjusted result.
- Pyrilutamide's reported androgen receptor IC50 is about 0.28 nM; RU-58841 has less formal published binding data.
- Research solutions are typically labelled 5% (50 mg/mL) for RU-58841 and 0.5% (5 mg/mL) for pyrilutamide.
- Neither compound holds a marketing authorisation in any country as of October 2026.
- Both block DHT at the androgen receptor in the scalp, working downstream of finasteride and dutasteride.
- Pyrilutamide has human clinical trial data. RU-58841 does not, only old animal studies and community reports.
- Different in-vitro binding data and labelled concentrations do not establish relative efficacy or safety in people.
- Neither is a licensed medicine. Everything here is for research use only.
The short answer
RU-58841 and pyrilutamide (KX-826) are both topical androgen receptor antagonists studied for pattern hair loss. The key difference is evidence: RU-58841 is a 1980s Roussel-Uclaf compound with animal data and no completed human trial, while pyrilutamide has company-reported trials, including a positive China Phase 3 and a US Phase 2 with no significant placebo-adjusted result. Neither is a licensed medicine.
How they both work
Both are topical androgen receptor (AR) antagonists. They sit on the androgen receptor inside the hair follicle and compete with dihydrotestosterone (DHT) for that binding site. If DHT cannot dock, it cannot drive the follicle miniaturisation that produces pattern hair loss.
This is a different point of attack from finasteride and dutasteride. Those reduce how much DHT your body makes systemically. RU-58841 and pyrilutamide leave DHT levels alone and simply block its effect locally, at the scalp. In theory that means the action stays where you put it, which is the whole appeal of a topical antiandrogen. In practice, how well that holds up depends on the compound, the concentration, and the carrier it is dissolved in.
The evidence gap
This is the single biggest difference between them, and most comparisons skip over it.
RU-58841: no human trials
RU-58841 was developed by Roussel-Uclaf in the 1980s and studied for acne, hirsutism and hair loss. Development was discontinued and it never completed human clinical trials. What exists is decades-old animal work, including a controlled study in stump-tailed macaques that showed regrowth, plus a very large body of anecdotal reports from people who have used it for years. That community record is genuinely useful signal, but it is not the same as controlled human data, and RU-58841’s safety profile in humans has never been formally established.
Pyrilutamide: actual clinical data
Pyrilutamide was designed from the start as a hair loss drug by Kintor Pharmaceutical. In March 2026 Kintor reported that KX-826 hit its Phase 3 primary endpoint in a 666-patient, 24-week, vehicle-controlled trial in China: about +15.3 hairs/cm2 from baseline at the 1.0% dose, roughly +10.65 hairs/cm2 over placebo (p<0.0001), with no drug-related serious adverse events reported. That is a real result. The caveats are equally real, though: it is company-reported top-line data, the trial was run entirely in China, and Kintor has faced repeated credibility questions from independent researchers. Promising signal, not a closed case.
Potency: pyrilutamide binds harder
On paper pyrilutamide is the more potent molecule. In binding assays its IC50 is around 0.28 nM, dramatically lower (stronger) than other topical AR antagonists like clascoterone. RU-58841 has less formal binding data published, but is generally considered less potent per molecule, which is part of why it is used at a much higher concentration (5% versus pyrilutamide’s 0.5%).
Potency on a lab bench is not the same as results on a scalp, though. DHT itself binds the receptor very tightly, so a topical has to reach a high enough local concentration to actually outcompete it. That is why the carrier and concentration matter as much as the raw binding number, and why the community’s real-world read is more nuanced than the assay data alone.
In practice: tolerability and reputation
Community reports are uncontrolled and cannot rank these compounds by tolerability or efficacy. The available trial reports for investigational pyrilutamide formulations do not establish a safety profile for the reference material sold here, and RU-58841 has no controlled human safety data. Neither should be described as side-effect-free.
None of that is a substitute for controlled long-term safety data, which neither compound has in full. It is the honest read of what people report, not a promise of how any given sample will behave.
Side by side
| RU-58841 | Pyrilutamide (KX-826) | |
|---|---|---|
| Mechanism | Topical AR antagonist | Topical AR antagonist |
| Human trials | None completed | Phase 3 (China, 666 patients) |
| Typical concentration | 5% | 0.5% |
| Developed by | Roussel-Uclaf, 1980s | Kintor Pharmaceutical |
| Binding potency | Less formal data | Very high (IC50 ~0.28 nM) |
| Track record | 20+ years community use | Newer, trial-backed |
| Comparative safety in humans | Not established | Not established for this material |
| Regulatory status | Never approved | Not approved outside China trials |
So which one comes out ahead?
Neither, on the evidence available in October 2026. Pyrilutamide has company-reported human trial data, including a positive China Phase 3 and a US Phase 2 with no significant placebo-adjusted result. RU-58841 has 1990s animal studies and no completed human trial. There is no head-to-head study, so no honest ranking of safety or efficacy exists.
Any source offering a universal answer is selling something. The comparison comes down to which kind of evidence gets weighted more heavily:
- RU-58841: no completed human trials; community reports are not controlled evidence.
- Pyrilutamide: company-reported human trial findings, including a missed US Phase 2 endpoint; no established safety or efficacy for this material.
One honest note on the pairing: they share the same mechanism (androgen receptor blockade), so combining them is not obviously additive the way pairing two different pathways would be: a live debate in the research community, not a claim about synergy.
The honest caveats
Neither RU-58841 nor pyrilutamide is a licensed medicine, and Norwood Labs makes no medical or treatment claims about either. We sell them strictly as reference materials for laboratory research use. RU-58841 has never passed human trials and its human safety profile is not established. Pyrilutamide’s clinical data is early, company-reported, and China-only. We do not give dosing advice. Published sample certificates document only the samples named in them.